SCHEMBL629470

SCHEMBL629470

C=CCC(C)(O)C(C)(C)O

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.36
TSHR P16473 1/20 0.30
ALOX15 P16050 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30907077 0.97 MAPT (0.35) MAPT
SCHEMBL20236060 0.92 MAPT (0.33) MAPT
Boric Acid SCHEMBL20236055 0.92 MAPT (0.33) MAPT
SCHEMBL27527153 0.82 MAPT (0.36) MAPTTSHRALOX15
SCHEMBL629330 0.80 MAPT (0.35) MAPT
SCHEMBL27727629 0.78 MAPT (0.34) MAPTTSHR
SCHEMBL8244794 0.75
SCHEMBL125434 0.75
SCHEMBL1537973 0.75
SCHEMBL20218688 0.74 MAPT (0.32) MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1219953-A Fabric softening compound/composition PROCTER & GAMBLE (US) 1999-06-16 CN claimed
CN-1195369-A Concentrated and stable fabric softening compositions PROCTER & GAMBLE (US) 1998-10-07 CN claimed
EP-3873504-B1 ADIPOCYTE MEDIATED DELIVERY OF ANTICANCER THERAPEUTICS UNIV NORTH CAROLINA STATE (US) 2023-12-13 EP disclosed
CN-112955162-B Adipocyte-mediated delivery of anticancer therapeutic agents 北卡罗莱纳州立大学 2023-10-13 CN disclosed
US-20210369787-A1 ADIPOCYTE MEDIATED DELIVERY OF ANTICANCER THERAPEUTICS NORTH CAROLINA STATE UNIVERSITY 2021-12-02 US disclosed
EP-3873504-A2 ADIPOCYTE MEDIATED DELIVERY OF ANTICANCER THERAPEUTICS North Carolina State University (US) 2021-09-08 EP disclosed
CN-112955162-A Adipocyte-mediated delivery of anticancer therapeutics 北卡罗莱纳州立大学 2021-06-11 CN disclosed
EP-1963292-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-02-22 EP disclosed
US-7700633-B2 Organic compounds NOVARTIS AG (CH) 2010-04-20 US disclosed
US-20080262050-A1 Organic Compounds NOVARTIS AG (CH) 2008-10-23 US disclosed
EP-1963292-A2 ORGANIC COMPOUNDS Novartis Pharma AG (CH) 2008-09-03 EP disclosed
WO-2007067615-A2 THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS NOVARTIS AG (CH) 2007-06-14 WO disclosed
CN-1195369-A Concentrated and stable fabric softening compositions PROCTER & GAMBLE (US) 1998-10-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262050-A1 Organic Compounds PTPRS, PTPRO, PTPRC MAPT 3222/4885TSHR 2240/4885ALOX15 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.